These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 28168639

  • 1. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P, Gilligan P, Mahon P, Sheahan R.
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [Abstract] [Full Text] [Related]

  • 2. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA.
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [Abstract] [Full Text] [Related]

  • 3. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C, Laggner AN, Domanovits H, Spiel AO.
    Europace; 2017 Feb 01; 19(2):233-240. PubMed ID: 28175295
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 01; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 5. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S, Hartikainen J, Ritz B, Juhlin T, Carbajosa-Dalmau J, Domanovits H.
    Cardiovasc Drugs Ther; 2021 Apr 01; 35(2):283-292. PubMed ID: 33206300
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 28; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 8. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 9. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
    Pohjantähti-Maaroos H, Hyppölä H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J.
    Eur Heart J Acute Cardiovasc Care; 2019 Mar 22; 8(2):114-120. PubMed ID: 28849946
    [Abstract] [Full Text] [Related]

  • 10. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N, Juhlin T, Öhlin B, Carlson J, Holmqvist F, Platonov PG.
    Ann Noninvasive Electrocardiol; 2015 Mar 22; 20(2):140-7. PubMed ID: 25040826
    [Abstract] [Full Text] [Related]

  • 11. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A.
    Expert Rev Cardiovasc Ther; 2014 Sep 22; 12(9):1067-75. PubMed ID: 25096598
    [Abstract] [Full Text] [Related]

  • 12. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 22; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 15. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D.
    Int J Cardiol; 2013 Oct 30; 169(2):95-6. PubMed ID: 24071384
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Vernakalant in hospital emergency practice: safety and effectiveness].
    Carbajosa Dalmau J, Cosín-Sales J, Pérez-Durá MJ, Noceda J, Urtubia-Palacios A, Hernández-Sori N, Peiró-Gómez A, Jacob J, Llorens P, Ruescas-Gómez L, Martín-Martínez A.
    Emergencias; 2013 Oct 30; 29(6):397-402. PubMed ID: 29188914
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May 30; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.